Clinical Trial Update: Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating plitidepsin (Aplidin) in combination with cytarabine for relapsed/refractory leukemia was terminated; results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia

Drugs mentioned

• Aplidin (plitidepsin)
• CYTARABINE (CYTARABINE)

Snippet

Sponsor: PharmaMar | Conditions: Relapsed/Refractory Leukemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2018-11-09